(Total Views: 311)
Posted On: 12/14/2017 9:46:39 AM
Post# of 30066
Three things I noted in today's PR
- This is not just a patent on MANF, but MANF AND CDNF.
- This is not just a patent on RP, but for retinal disorders including RP AND Glaucoma
- Another patent extended out to the year twenty thirty plus
https://www.amarantus.com/news/press-releases...-announces
- This is not just a patent on MANF, but MANF AND CDNF.
- This is not just a patent on RP, but for retinal disorders including RP AND Glaucoma
- Another patent extended out to the year twenty thirty plus
Quote:
In addition, Amarantus' wholly-owned subsidiary MANF Therapeutics, Inc. was issued a patent by the Japan Patent Office entitled "Method of Treatment for Retinal Disorders" covering the use of MANF and cerebral dopamine neurotrophic factor (CDNF) as treatments for retinal disorders, including Retinitis Pigmentosa (RP) and Glaucoma. The issued patent extends coverage for MANF Therapeutics use of MANF and CDNF in the treatment of retinal disorders in Japan into 2031
https://www.amarantus.com/news/press-releases...-announces
(7)
(0)
